a fragment of a fragment
1990-1993 (Monash discovery/first publication); 1997-2007 (Metabolic Pharmaceuticals patent-to-trial-failure arc)
AOD-9604 flunked the one job it was built for — shrinking waistlines in a 536-person obesity trial — yet outlived that failure for nearly two decades, sold worldwide in gray-market fat-loss vials on the strength of its spotless safety data alone.
In the early 1990s, a Monash University biochemist named Frank Ng asked a smaller, sharper question than everyone else chasing growth hormone. Instead of 'does growth hormone burn fat,' he wanted to know exactly which sliver of the 191-amino-acid hGH molecule did the fat-burning — and whether that sliver could be snipped free of the parts that cause GH's uglier side effects, from bone and organ overgrowth to insulin resistance. His group found the answer in the molecule's tail: the C-terminal fragment (roughly residues 177-191) reproduced hGH's fat-mobilizing punch all by itself in rat fat tissue, no growth-signaling machinery required. Wu and Ng published it in 1993 — real, PubMed-indexed primary literature, not an origin myth.
An ASX-listed Melbourne biotech, Metabolic Pharmaceuticals, licensed the discovery, synthesized a stabilized 16-amino-acid version (with a tyrosine tacked onto one end for stability), and gave it a name that could only have come from a spreadsheet: AOD9604 — Anti-Obesity Drug, compound 9604. The pitch was irresistibly tidy: all of growth hormone's fat-burning power, none of its growth-promoting or blood-sugar baggage, because the fragment never engages the GH receptor's growth machinery. The company patented it in 1997 (granted 2003), then poured a reported $50-60 million and six human trials — some 900 to 925 subjects — into chasing an obesity drug.
The early numbers teased. A 12-week Phase IIa trial of roughly 300 people showed a modest but real edge over placebo, about 2.6-2.8 kg lost versus 0.8 kg. Then came the pivotal OPTIONS trial — 24 weeks, 536 subjects, oral doses up to 1 mg a day — and not a single treatment arm beat placebo on weight loss. Metabolic terminated the obesity program in March 2007. The strange part is what didn't fail: across all six trials the drug's safety profile was indistinguishable from placebo — no IGF-1 spike, no glucose disturbance, no antibody response. A drug that couldn't do its one job, yet was almost eerily hard to hurt anyone with.
That combination — useless but harmless — is exactly the kind of molecule that refuses to die. Metabolic Pharmaceuticals rebranded as Calzada Ltd and, rather than shelving the compound, aimed it at an entirely new target: cartilage and joint repair, with lab and rabbit-model osteoarthritis studies running into the mid-2010s — a genuine second act most of its obituaries skip. And far from any legitimate lab, that same spotless safety record and hGH pedigree turned AOD-9604 into a permanent fixture of the research-peptide and gray-market fat-loss trade: a drug approved nowhere, that somehow never disappeared.
Almost all of this checks out — the 1993 Wu & Ng paper, the null OPTIONS trial, the 2007 shutdown, the Calzada-era joint-research pivot, and the WADA and TGA bans are all solidly and independently sourced. The one stretch: the December 2024 FDA setback wasn't a quiet "decline" but a blunt 0-12 advisory-committee vote against it, and the development cost is best cited as a $50-60 million range rather than a single precise figure.
AOD-9604 has never been approved by the FDA, the TGA, or any national regulator for any human use — the obesity program that created it died in 2007, and no company has carried it to approval since. The <b>World Anti-Doping Agency</b> prohibits it (folded into its S2 growth-hormone-fragment category, with prohibited status clarified by 2013), and Australia made it Schedule 4, prescription-only, in a 2015 sweep of growth-hormone-related peptides. In December 2024 the FDA's Pharmacy Compounding Advisory Committee voted 0-12 against adding AOD-9604 (both free base and acetate forms) to the 503A compounding bulks list, citing immunogenicity risk, peptide-related impurities, and limited long-term safety data. Yet it's still sold widely through research-chemical channels labeled "not for human use" — and its most credible legitimate future may be the barely-publicized joint-and-cartilage research, not the fat-loss story most buyers know it for.
